Gamida's Omisirge therapy FDA approved for blood cancer treatment.
TL;DR Summary
The US FDA has approved the use of Gamida Cell's cell therapy, Omisirge, for reducing the risk of infection in patients undergoing treatment for blood cancer. The therapy is given as a single intravenous dose and is made using donor stem cells obtained from umbilical cord blood. The approval is based on a late-stage study that showed a quicker recovery of neutrophils in patients taking Omisirge, compared with those who received umbilical cord blood transplantation.
- US allows use of Gamida's therapy in blood cancer treatment Reuters
- Struggling Gamida wins long-awaited FDA approval for Omisirge FiercePharma
- Gamida Cell’s Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval Yahoo Finance
- Gamida cell therapy Omisirge for blood cancer FDA approved Seeking Alpha
- FDA Approves Omisirge to Reduce Infection Risk in Patients With Blood Cancer Curetoday.com
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
73%
282 → 75 words
Want the full story? Read the original article
Read on Reuters